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Abstract
Obstructive sleep apnea (OSA) is a highly prevalent disease, and is traditionally associated with increased cardiovascular
risk. The role of comorbidities in OSA patients has emerged recently, and new conditions significantly associated with
OSA are increasingly reported. A high comorbidity burden worsens prognosis, but some data suggest that CPAP might
be protective especially in patients with comorbidities. Aim of this narrative review is to provide an update on recent
studies, with special attention to cardiovascular and cerebrovascular comorbidities, the metabolic syndrome and type
2 diabetes, asthma, COPD and cancer. Better phenotypic characterization of OSA patients, including comorbidities, will
help to provide better individualized care. The unsatisfactory adherence to CPAP in patients without daytime
sleepiness should prompt clinicians to examine the overall risk profile of each patient in order to identify subjects
at high risk for worse prognosis and provide the optimal treatment not only for OSA, but also for comorbidities.
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Obstructive sleep apnea (OSA) is highly prevalent in the
general population, and occurs at all ages [1]. OSA is char-
acterized by collapse of upper airways during sleep with
ineffective respiratory efforts, intermittent hypoxia and
sleep disruption. Continuous positive airway pressure
(CPAP), mandibular advancement devices, and upper
airway (UA) and maxillo-facial surgery are therapeutic
options that prevent UA closure during sleep, CPAP being
the gold standard for moderate-severe OSA. The typical
OSA patient is overweight or obese, sleepy in passive
situations or while driving, and often affected by systemic
hypertension, type 2 diabetes, and dyslipidemia [1].
The frequent association of OSA with metabolic and
cardiovascular diseases has been recognized since the
early studies, but the role of OSA as an independent risk
factor has long remained controversial due to the presence
of powerful confounders, such as hypertension and
obesity [2]. Interest in the role of comorbidities in OSA
has grown in the last decade, as shown by the rising num-
ber of publications on the topic (Fig. 1). This review will
examine some epidemiological aspects of comorbidities in
OSA, and summarizes the current state of the art on the
most frequent comorbidities encountered in clinical prac-
tice in OSA patients.
Comorbidities in OSA: the size of the problem
Currently, comorbidities are a major topic in clinical re-
search on OSA. Several recent studies reported a high
prevalence of comorbidities in OSA patients [3–6] (Fig.
2). The distribution of comorbidities differed between
men and women, with diabetes and ischemic heart dis-
ease being more prevalent in men with OSA, and hyper-
tension and depression being more prevalent in women
with OSA compared to non-OSA subjects [3, 7]. Ac-
cording to some studies, the comorbidity burden pro-
gressively increases with OSA severity [5, 6, 8, 9].
A recent study from Taiwan in a large number of OSA
patients analyzed prevalence of comorbidities at diagnosis
and their relationship with mortality risk during follow up
[10]. The study confirmed that OSA patients show a high
prevalence of cardiovascular diseases (systemic hyperten-
sion, coronary artery disease, arrhythmias, ischemic
stroke), respiratory diseases (COPD, asthma), and meta-
bolic disorders (diabetes mellitus, dyslipidemia, gout).
Many other disorders were also identified, including pep-
tic ulcer disease, gastroesophageal reflux, chronic liver
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disease, anxiety, insomnia, and depression. The authors
identified ten comorbid conditions associated with
increased mortality risk, and developed a comorbidity
score for OSA by taking into account the relative risk
associated with each disease state and the number of co-
morbidities. Such an approach allows to focus on those
comorbidities that are prognostically more relevant in
OSA. For example, the highest risk was associated with
end-stage renal disease and aortic aneurysm, which
showed the lowest prevalence in the sample [10]. In
addition, the higher the comorbidity score, the higher the
mortality risk [10]. Unfortunately, the impact of OSA
treatment was not evaluated in detail.
Comorbidities and mortality in CPAP-treated OSA
Other studies on the prognostic impact of comorbidities in
OSA patients examined the effects of CPAP treatment. In a
large study from Denmark, negative predictors for survival
were male gender, age ≥60 years, no CPAP treatment, prior
comorbidity, and low educational level [11]. Another study
found that age and occurrence of comorbidities predicted
mortality in OSA patients [12]. In patients aged >50 years,
protective effects of CPAP treatment were shown only in
patients with comorbidities [12]. In patients with moderate-
severe obesity and OSA, treatment with CPAP or noninva-
sive ventilation was associated with fewer cardiovascular
events only in patients with a high number of comorbidities
Fig. 1 Retrieval of references by searching PubMed for “obstructive sleep apnea” and comorbidities, 9 Jan 2019
Fig. 2 Differently from other common sleep disorders, 80% of patients with obstructive sleep apnea (OSA) show multiple comorbidities. RLS:
restless leg syndrome. Drawn based on data from [5]
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[13]. The protective effect of CPAP might be larger in males
than females with OSA [14, 15]. Other observational
studies reported a protective effect of CPAP treatment in
elderly OSA patients, who usually show a high prevalence
of cardiometabolic comorbidities [16, 17].
Therefore, occurrence of comorbidities could identify
subgroups of OSA patients at high risk, who might show
benefit from CPAP treatment. Several studies have tried
to define clinical phenotypes of OSA, and a cluster of
patients with few OSA symptoms but high comorbidity
burden has been reported by most studies published so
far; such a cluster at least partly overlaps with the cluster
of elderly OSA patients [18]. More recent analyses
pointed to sleep fragmentation and hypoxia as risk
factors for cardiovascular events or death, and regular
CPAP use appeared to exert a protective effect [19].
Common comorbidities in OSA patients
A comprehensive review of all possible comorbidities as-
sociated with OSA is beyond the scope of this article.
Only the most frequent diseases will be discussed, with
special attention to the most recent publications.
Cardiovascular and cerebrovascular diseases
Many studies have examined the role of OSA as a patho-
genetic factor in cardiovascular and cerebrovascular dis-
eases, as well as the potential protective effects of CPAP
treatment. OSA may increase cardiovascular risk through
multiple intermediate mechanisms, such as intermittent
hypoxia, high sympathetic nervous activity, systemic
hypertension, endothelial cell dysfunction, oxidative stress,
inflammation, and accelerated atherosclerosis [1]. On the
other hand, chronic intermittent hypoxia could also acti-
vate some protective mechanisms, for example through
the development of coronary vessel collaterals in patients
with ischemic heart disease [20, 21].
Systemic hypertension
The best studied cardiovascular comorbidity in OSA is
systemic hypertension [22]. Respiratory events during
sleep are associated with hypertensive peaks occurring at
the end of apneas and hypopneas, increased mean noc-
turnal blood pressure, and increased variability of blood
pressure [23]. A dose-response relationship has been
shown between OSA severity and blood pressure [24].
OSA patients may show elevated blood pressure values
during sleep only, or during sleep and wakefulness,
making 24-hour monitoring of blood pressure highly
advisable in the OSA population [22]. Resistant hyper-
tension, i.e. incomplete blood pressure control on three
antihypertensive drugs, is also frequent in OSA patients.
Several studies assessed the potential benefit of CPAP
treatment on blood pressure values, and meta-analyses
demonstrated that on average blood pressure decreased
by only a small amount during CPAP treatment. However,
the therapeutic effect of CPAP on hypertension varied
according to OSA severity, compliance to CPAP treat-
ment, and baseline blood pressure values [25]. OSA pa-
tients with resistant hypertension showed a quite large
decrease in blood pressure during CPAP [26]. Antihyper-
tensive drugs, and diuretics in particular, may slightly de-
crease AHI in OSA [27]. In general, pharmacological
treatment to control hypertension is necessary in hyper-
tensive OSA patients, given the small effects of CPAP on
blood pressure [28, 29].
Cardiovascular events and/or death
Several studies have addressed the question of OSA
and cardiovascular morbidity and mortality. The pro-
spective cohort study by Marin and coworkers
reported a high cardiovascular risk in patients with
severe OSA, which was normalized by CPAP treat-
ment [30]. The results of observational studies con-
firmed the association of untreated OSA with overall
and cardiovascular mortality [31]. In patients under-
going percutaneous coronary intervention, OSA was
associated with occurrence of cardiovascular events
during follow up [32, 33].
Randomized controlled trials (RCTs) in OSA patients
with known coronary artery or cerebrovascular disease
were then designed to verify whether treatment of OSA
in patients at high cardiovascular risk might exert a pro-
tective role. However, RCTs on the effects of CPAP in
patients with known coronary or cerebrovascular disease
failed to show any protective effect of CPAP treatment
on cardiovascular risk [34]. Current uncertainty is due
to the discrepancy between data obtained from observa-
tional studies and RCTs [35]. Different patients’ charac-
teristics according to the type of study may explain the
different results. In particular, only patients without ex-
cessive daytime sleepiness were included in long-term
RCTs, since it would be unethical to withdraw treatment
in symptomatic patients. It is known that compliance to
CPAP treatment in non-sleepy patients is low, as under-
lined in a recent pro-con debate [36, 37]. Good compli-
ance to CPAP, i.e. mean nightly use ≥ 4 hours, was
associated with some protection, especially for occur-
rence of stroke [38].
Another area of current interest is whether OSA may
modify the outcomes of acute coronary syndromes (ACS).
OSA prevalence is high in patients with ACS, and severe
OSA occurs in 25% of the patients [39]. The ongoing
ISAACC trial (Impact of Continuous Positive Airway
Pressure on Patients with ACS and Nonsleepy OSA) will
provide long-term data on the effects of treating OSA in
this population [40].
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Arrhythmias
Arrhythmias are frequent in OSA patients, especially
atrial fibrillation (AF). A permissive role of OSA towards
the arrhythmogenic mechanism of AF is suggested by
the higher risk of recurrence of AF in patients with OSA
compared to non-OSA subjects and by the protective
effect of CPAP treatment [41, 42]. Conversely, the litera-
ture on ventricular arrhythmias is relatively scarce and
heterogeneous, as pointed out by a recent review [43].
Incidence of sudden cardiac death is increased at night
in OSA according to some reports [44] while other stud-
ies found a uniform distribution over 24 hours [45].
Studies in patients with implantable cardioverter-defibril-
lator devices (ICD) have reported a high frequency of noc-
turnal discharge in OSA compared to non-OSA patients
[46] or patients with chronic heart failure and central ap-
neas [47, 48].
Cerebrovascular disease
Several studies reported an increased risk of stroke in
snorers [49] and OSA patients [50]. CPAP treatment
may reduce the risk of stroke [51], but most studies have
used a composite cardiovascular outcome including
stroke, rather than reporting data for each type of
events. Available RCTs on the effects of CPAP in
patients with stroke and OSA are usually short-term,
and the low acceptance of CPAP treatment in patients
with OSA and previous stroke is an additional difficulty
to be considered. A recent meta-analysis on RCTs in the
latter population reported improvement in neurological
function in CPAP users [52]. More studies are necessary
to evaluate the possible protective effects of CPAP on
survival after stroke.
Metabolic diseases
The relationship between OSA and metabolism is highly
complex. On one hand, OSA is often associated with
obesity, which by itself is characterized by disturbed en-
ergy metabolism and adipose tissue inflammation [53].
On the other hand, nocturnal intermittent hypoxia has
been shown to affect glucose metabolism, and OSA
could independently contribute to the pathogenesis of
metabolic disorders [54]. The bidirectional relationships
between OSA and disturbed energy metabolism [55] or
type 2 diabetes [56] are current topics of interest, given
the obesity epidemics and the increasing prevalence of
type 2 diabetes worldwide.
OSA and the Metabolic Syndrome
The metabolic syndrome (MetS), a pre-diabetic state asso-
ciated with central obesity and increased cardiovascular
risk [57], is highly prevalent in OSA patients [58] and,
according to some authors, OSA should be considered as
an additional manifestation of MetS [59]. OSA may play a
role in the pathogenesis of insulin resistance, the main
feature of MetS, through intermittent hypoxia [60, 61] and
sleep loss or fragmentation [62–64]. A fascinating recent
research area is represented by the role of gut microbiota
in metabolic derangements induced by intermittent
hypoxia [65, 66] or sleep fragmentation [67]. Readers
interested in the complex mechanisms of the interaction
between OSA/intermittent hypoxia, adipocyte dysfunc-
tion, and inflammatory activation in adipose tissue, are
referred to extensive reviews on these topics [68–71].
Although a positive effect of OSA treatment on meta-
bolic disturbances might be expected based on the patho-
physiological links described above, CPAP treatment does
not modify visceral fat or metabolic variables [72, 73]
unless concurrent weight loss occurs [74]. Nevertheless,
short-term CPAP treatment for 8 hours/night improves
insulin resistance, suggesting that prolonged nightly treat-
ment with CPAP may be needed to modify glucose metab-
olism in OSA, possibly through decreased sympathetic
activation [75]. Activity of insulin in the carotid body, and
a common pathway involving both intermittent hypoxia
and metabolism, is an interesting recent pathogenetic
hypothesis possibly explaining the intertwining effects of
OSA and glucose dysmetabolism [76].
OSA and diabetes
The bidirectional relationship between OSA and dia-
betes is especially interesting from a clinical point of
view [77]. Treatment of OSA may help to prevent severe
consequences of diabetes. This might indeed be the case,
since although glycemic control does not improve dur-
ing CPAP treatment according to meta-analyses [78, 79],
untreated OSA in diabetic patients is associated with
increased prevalence of neuropathy [80], peripheral
arterial disease [81], diabetic retinopathy [82] and dia-
betic nephropathy [83–85]. Data on the effects of CPAP
on diabetic complications are scarce. Compared to
poorly compliant patients, optic nerve function im-
proved in severe OSA patients with good compliance to
CPAP treatment [86]. A recent post-hoc analysis of data
from the SAVE study highlighted a higher risk of adverse
outcomes in diabetic compared to non-diabetic patients,
and a protective effect of CPAP on recurrent cardiovas-
cular events only in diabetic patients with OSA showing
a good adherence to CPAP treatment, i.e. at least 4 h/
night, in the first 2 years of the study [87].
In summary, OSA may worsen metabolic abnormal-
ities, and OSA treatment with sufficient adherence could
play a protective role, especially when concomitant life-
style interventions and weight loss are implemented.
Screening for OSA in diabetic patients should be sys-
tematically done, since CPAP treatment for at least 4 h/
night may be protective, especially when diabetic com-
plications are also present [88].
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Renal disease
Renal diseases and OSA share common risk factors, like
arterial hypertension, diabetes mellitus, obesity and
advanced age. Each of such factors may give some inde-
pendent contribution to the onset and progression of
the other one [89]. OSA may endanger the kidney through
several interacting mechanisms, including nocturnal inter-
mittent hypoxemia, recurrent nocturnal blood pressure
peaks, sympathetic hyperactivity, hyperactivation of intrare-
nal renin-angiotensin system, oxidative stress and systemic
inflammation, endothelial dysfunction. A relationship
between nocturnal hypoxemia and hyperactivation of the
intrarenal renin-angiotensin system has been experimen-
tally demonstrated [90].
Cross-sectional epidemiological studies have not con-
sistently reported an association between OSA and
either albumin excretion or eGFR. When an association
was found, either severity of nocturnal hypoxemia [91]
or the apnea/hypopnea index [92] were reported to cor-
relate to renal alterations. These studies highly differed
in design, sample size, recruitment criteria (patients
referred to sleep laboratories, general population, dia-
betes as an inclusion or an exclusion criterion), so that it
is difficult to draw firm conclusions from them.
More interesting and consistent results were obtained
from longitudinal investigations. In a large study on US
veterans, the annual rate of decline of eGFR was higher
among patients diagnosed with sleep apnea than among
controls [93]. Three retrospective cohort studies in
Taiwan found a higher incidence of chronic kidney disease
(any stage) among OSA than control subjects [94–96].
However, all these studies lacked polysomnographic infor-
mation about OSA severity. Another longitudinal study
on patients recruited in a sleep laboratory found that an
accelerated decline in eGFR was more common among
subjects who spent >12% of sleep time with oxygen
saturation <90% than in less hypoxic subjects [97]. By
contrast, a long-term study on the population-based
Wisconsin Sleep Cohort did not find any difference in
the rate of decline of eGFR between subjects initially
showing an AHI>15 and other subjects [98]. However,
the less severe nocturnal hypoxemia in sleep apnea
subjects from the general population may at least partly
explain the different results obtained in the Wisconsin
cohort and in studies on OSA patients.
Most papers on the effects of OSA treatment on kid-
ney function showed positive effects of CPAP. Two small
studies on subjects with a high baseline GFR found a
reduction of filtration fraction due to decrease in glomeru-
lar hyperfiltration [99, 100]. Two other small studies on
subjects with mildly or severely impaired renal function
observed an increase in eGFR [101] or a decrease in eGFR
decline [102]. More recently, a RCT could not demonstrate
a difference in the rate of eGFR decline between subjects
with OSA and cardiovascular diseases treated by CPAP or
under “usual care”; however, the power of the study could
be insufficient to demonstrate a difference between the
two groups [103]. In a study with a larger number of pa-
tients recruited in different sleep laboratories, therapy with
fixed CPAP, but not with autoadjusting CPAP, could blunt
the spontaneous trend of eGFR to decline over time [104].
In summary, there is some evidence that OSA may
worsen kidney function through several mechanisms,
and CPAP may exert beneficial effects.
COPD
Both OSA and chronic obstructive pulmonary disease
(COPD) are common and may occur in the same
patient. Their association is known as “overlap syn-
drome” since the early studies [105]. Prevalence of the
overlap syndrome has been reported at 1.0 to 3.6% in
the general population, 8-56% in OSA patients, and
3-66% in COPD patients [106]. In OSA patients, preva-
lence of the overlap syndrome was found to increase
with age, in agreement with COPD being more prevalent
in elderly than middle-aged subjects [106]. In COPD
patients, prevalence of respiratory events during sleep
was high, with sleep disordered breathing (SDB) in 66%
of patients with moderate to severe COPD [107]. In COPD
patients undergoing pulmonary rehabilitation an AHI≥15/h
was found in 45% of the sample [108]. COPD patients often
show poor sleep quality [109, 110] and hypoventilation
during sleep [111]. Use of oxygen during sleep could
contribute to diagnostic uncertainty regarding OSA
[107]. In addition, insufficient data are available on the
role of either COPD or OSA severity on the clinical
presentation or outcomes of the overlap syndrome,
since the consequences of severe OSA associated with
mild COPD may differ from those of mild OSA associ-
ated with severe COPD.
As outcomes are concerned, early studies reported
lower PaO2 and higher PaCO2 in overlap patients com-
pared to OSA patients with a similar AHI, associated
with higher pulmonary artery pressure at rest and during
exercise [112]. More recent observational studies
reported increased mortality in overlap patients com-
pared to OSA patients [113–115], and a protective effect
of CPAP treatment [113, 116, 117]. By contrast, a com-
plex study in over 6,000 subjects from the general popu-
lation recently reported that mortality was higher in
patients with SDB defined as AHI≥5, but occurrence of
SDB and SDB severity could mitigate the effects of
decreasing FEV1 on mortality [118]. These data suggest
that OSA and COPD pathophysiology may interact, with
low body mass index (BMI) and lung hyperinflation
protecting against OSA in COPD, and upper airway and
systemic inflammation in COPD potentiating the detri-
mental effects of OSA [119, 120]. Better phenotypic
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characterization of patients with overlap syndrome is
needed, to optimize therapeutic strategies of both diseases.
Asthma
Asthma and obstructive sleep apnea (OSA) are highly
prevalent disorders which are often associated [121]. OSA
symptoms are frequent in asthmatic patients [122–126],
who also report daytime sleepiness [127], poor asthma
control [128–131], and reduced quality of life [132].
Longitudinal data from the Wisconsin Sleep Cohort
suggested that asthma at baseline increased the risk to
develop OSA during follow up [133].
Sleep studies confirmed that OSA is more common in
asthmatics than in controls [134–136], and OSA resulted
associated with a higher frequency of asthma exacerba-
tions [136]. Mild-moderate OSA occurred in 49% of
patients with difficult-to-treat asthma [137]. Patients
with severe asthma showed increased apnea-hypopnea
index (AHI), poor sleep quality and daytime sleepiness
[138]. However, lower airway resistance was shown to
increase in asthmatic patients during slow wave sleep,
whereas upper airway resistance remained low [139].
Moreover, hypopneas rather than apneas were the main
type of respiratory events recorded in asthmatic patients
[138]. On the other hand, upper airways in patients with
OSA and asthma were shown to be smaller than in
patients with either disease or controls, suggesting a
synergistic role on upper airway inflammation played by
both OSA and asthma [140].
In patients with suspected or confirmed OSA, some
studies highlighted the association of asthma and obesity,
especially in women [141–143]. In the European Sleep
Apnea Database (ESADA), OSA and asthma were
frequent in obese women [144]. A community-based
study in Uppsala reported worse sleep quality and occur-
rence of nocturnal hypoxemia in women with both OSA
and asthma, who showed higher BMI compared to
controls or women with either asthma or OSA [145].
Other studies reported a positive relationship between
severity of OSA and severity of asthma symptoms [138],
higher prevalence of mild-moderate rather than severe
OSA in patients with asthma [135, 143] or no relationship
between asthma and OSA severity [6]. In the ESADA
cohort, the distribution of OSA severity was similar in
patients with and without physician-diagnosed asthma,
and unaffected by treatment for asthma or for gastro-
esophageal reflux [144]. These differences in results
among studies may at least partly reflect variable referral
patterns for sleep studies in asthmatic patients, and
further studies are needed to better define the real impact
of OSA in asthma, and of asthma in OSA.
It is still uncertain whether treatment of OSA with
continuous positive airway pressure (CPAP) might im-
prove asthma control or pulmonary function. Some
studies reported positive results [146–148] while other
studies were negative [149, 150]. One study reported a
decreased rate of FEV1 decline in asthmatic patients
treated with CPAP [136], but the majority of studies
agree on unchanged pulmonary function after CPAP. A
recent systematic review pointed out that results of
different studies do not allow to document a definite
improvement in asthma control, although a positive
effect of CPAP treatment seems to occur in patients with
severe OSA or poorly controlled asthma [151].
In summary, the association of asthma and OSA would
benefit from careful phenotyping of both diseases. Neutro-
philic rather than eosinophilic inflammation was found in
asthmatic patients with OSA [137, 152], suggesting a pos-
sible contribution of OSA to neutrophilic asthma. Further
studies are needed to assess whether CPAP treatment
could be a useful adjunct of asthma treatment in OSA
patients, especially in cases of poorly controlled asthma.
Cancer
The association of OSA and cancer has been explored
in the last few years. In mice bearing human subcutane-
ous melanoma xenografts, intermittent hypoxia expos-
ure accelerated tumor progression, and was associated
with both metastases and resistance to treatment [153].
Such an effect was possibly mediated by activation of
the hypoxia inducible factor (HIF) 1-alpha pathway
[153, 154].
Epidemiological and clinical studies have explored the
association of OSA and cancer in humans. Cancer mor-
tality during follow up was increased in OSA patients
compared to controls in general population samples
[155, 156], cohorts of OSA patients [157], and cohorts
of cancer patients [158], in association with OSA severity
and duration of nocturnal hypoxemia. Some studies how-
ever did not show increased mortality associated with
occurrence of OSA in the general population [159] or
cohorts of cancer patients [160, 161].
Other studies reported increased incidence of can-
cer in cohorts of OSA patients compared to controls
[156, 159, 162–165]; however, two population-based
studies were negative [166, 167], but one study assessed
only OSA symptoms rather than collecting objective sleep
data [166]. According to some reports, incidence of
cancer was especially high in relatively young OSA
patients [157, 162]. Two studies assessing different
cancer localizations reported a high risk of pancreatic
cancer and melanoma in OSA patients, whereas risk for
colorectal cancer was relatively low compared to non-
OSA subjects [159, 160]. Therefore, although most studies
indicate that intermittent hypoxia in OSA may increase
cancer risk, firm evidence is still lacking, as confirmed by
results of two recent meta-analyses [168, 169].
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A series of studies focused on the association of OSA
and cutaneous malignant melanoma (CMM), to verify
whether data from the mouse model could be confirmed
in humans. Tumor aggressiveness was increased in
CMM patients with OSA and long time spent at low
oxygen saturation (CT90%) or high oxygen desaturation
index (ODI 4%) [158, 170–173]. Interestingly, tumor ag-
gressiveness was positively associated with expression of
the adhesion molecule VCAM-1 [171], HIF-1alpha
[173], but not with expression of vascular endothelial
growth factor (VEGF) [173]. Similar results were re-
ported in patients with lung cancer and OSA [158].
In summary, the association of OSA and cancer is bio-
logically plausible, as shown by the experimental studies
using the intermittent hypoxia model. Human data on in-
cidence of cancer and mortality in OSA patients confirm
experimental data, especially in cohorts of CMM patients.
However, no definitive evidence is available, and further
studies are required especially concerning the possible
higher risk of cancer in young OSA patients. Moreover,
no study has assessed the potentially protective role of
CPAP treatment, and studies based on administrative data
often lack adjustments for known risk factors for cancer.
Conclusions
Comorbidities are frequent in OSA patients, and OSA
appears as a potential trigger for worse prognosis by
worsening chronic organ damage [174], justifying the
hypothesis of a dangerous liaison between OSA and co-
morbidities. Although the possible protective role of
OSA treatment is still uncertain, it could differ among
different clinical phenotypes of OSA patients. In that re-
gard, studies are still moving their first steps [18, 175],
but some data are available showing different responses
depending on OSA phenotype [19]. Such view is con-
firmed by the recent report developed by European ex-
perts on OSA, which suggests that both symptoms and
organ damage should be considered when choosing the
appropriate treatment for OSA [174]. Although person-
alized medicine is slowly developing in the OSA field,
testing a model similar to the model developed for
COPD might provide useful hints on the possible detri-
mental role of comorbidities in OSA patients and
suggest the best therapeutic approaches. Moreover, it is
necessary to consider the role of comorbidities in elderly
OSA patients and women with OSA, given the differences
in pathophysiology and clinical presentation compared to
the usual model of middle-aged men that dominates the
current literature. Careful assessment of comorbidities
should become standard clinical practice for OSA patients.
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